Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing
July 20 2021 - 7:00AM
Business Wire
- IMM-BCP-01 already shown to neutralize all
other CDC variants of concern in pre-clinical
testing
- IND submission planned for this
quarter
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that
utilizes its human memory B cell platform to discover and develop
first-in-class antibody therapeutics, announced today that its
three-antibody cocktail (IMM-BCP-01) has demonstrated potent
neutralizing activity against the SARS-CoV-2 Delta variant in
pre-clinical pseudovirus testing. Furthermore, IMM-BCP-01 showed
in-vitro activity via non-neutralizing mechanisms, such as
complement fixation, which Immunome expects will enable viral
clearance.
“IMM-BCP-01’s ability to maintain neutralizing activity against
emerging SARS-CoV-2 variants, including the Delta variant,
potentially positions our drug candidate as a long-term solution to
the changing threat posed by COVID-19. We believe our lead
candidate’s mechanism of action, targeting at least three
non-overlapping epitopes - informed by authentic human immune
response - provides a robust defense against future mutational
drift,” said Purnanand Sarma, PhD, President & CEO of Immunome.
“Currently, the delta variant accounts for a majority of
coronavirus cases in the United States.”
Immunome was awarded a $17.6 million technology award from the
U.S. Department of Defense's Joint Program Executive Office for
Chemical, Biological, Radiological and Nuclear Defense
(JPEO-CBRND), in collaboration with the Defense Health Agency, to
support Immunome’s COVID program.
Given the near-term potential for a resurgence of COVID-19
infections driven by emerging variants, Immunome intends to explore
opportunities to expedite the development of this potential
therapeutic. The Company plans to submit an IND application with
the U.S. Food and Drug Administration (FDA) this quarter.
About Immunome
Immunome is a biopharmaceutical company that utilizes its
proprietary human memory B cell platform to discover and develop
first-in-class antibody therapeutics that are designed to change
the way diseases are treated. The company’s initial focus is on
developing therapeutics to treat oncology and infectious diseases,
including COVID-19. Immunome’s proprietary discovery engine
identifies novel therapeutic antibodies and their targets by
leveraging the highly educated components of the immune system,
memory B cells, from patients whose bodies have learned to fight
off their disease. For more information, please visit
www.immunome.com.
Forward-Looking Statements
This press release includes certain disclosures that contain
“forward-looking statements” intended to qualify for the “safe
harbor” from liability established by the Private Securities
Litigation Reform Act of 1995, as amended, including, without
limitation, express or implied statements regarding Immunome’s
beliefs and expectations regarding the advancement of its COVID-19
therapeutic antibody programs, execution of its regulatory,
clinical and strategic plans, anticipated upcoming milestones for
IMM-BCP-01, including expectations regarding therapeutic potential
and benefits thereof, and IND submission. Forward-looking
statements may be identified by the words “anticipate,” believe,”
“estimate,” “expect,” “intend,” “plan,” “project,” “may,” “will,”
“could,” “should,” “seek,” “potential” and similar expressions.
Forward-looking statements are based on Immunome’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Factors that could cause
actual results to differ include, but are not limited to, those
risks and uncertainties associated with: the impact of the COVID-19
pandemic on Immunome’s business, operations, strategy, goals and
anticipated milestones; Immunome’s ability to execute on its
strategy including with respect to the timing of its R&D
efforts, IND filings, initiation of clinical studies and other
anticipated milestones; Immunome’s IND submission and other
regulatory filings, timing of these filings and governmental
authority feedback regarding the same; the timing and effectiveness
of any antibody therapeutics which may be developed by Immunome;
Immunome’s ability to fund operations; and the additional risks and
uncertainties set forth more fully under the caption “Risk Factors”
in Immunome’s Annual Report on Form 10-K filed with the United
States Securities and Exchange Commission (SEC) on March 25, 2021,
and elsewhere in Immunome’s filings and reports with the SEC.
Forward-looking statements contained in this announcement are made
as of this date, and Immunome undertakes no duty to publicly update
or revise any forward looking statements, whether as a result of
new information, future events or otherwise, except as may be
required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210720005506/en/
Immunome Contact Corleen Roche Chief Financial Officer
Immunome, Inc. investors@immunome.com Investor Contact
Laurence Watts Managing Director Gilmartin, LLC
laurence@gilmartinir.com Immunome Media Contact Megan
McGrath or Nick Chang MacDougall 781-235-3060
mmcgrath@macbiocom.com or nchang@macbiocom.com
Immunome (NASDAQ:IMNM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Immunome (NASDAQ:IMNM)
Historical Stock Chart
From Sep 2023 to Sep 2024